Corporate Corruption News Stories

Excerpts of Key Corporate Corruption News Stories in Major Media

Below are key excerpts of revealing news articles on corporate corruption from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

Note: This comprehensive list of news stories is usually updated once a week. Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.

A federal advisory committee on Tuesday recommended approval of the first bird flu vaccine for humans, despite concerns about its safety and evidence that the shots won't protect most people. The panel said although the vaccine had significant shortcomings, it was safe and effective for use during a pandemic or in high-risk situations, such as military deployment to regions facing an outbreak. The government plans to buy and stockpile enough doses for 20 million people. [The] director of the FDA's vaccine office told the panel that the vaccine was a stopgap measure. "There are numerous vaccines under development that are potentially better than this one," he said. The bird flu strain known as H5N1 originated in Asia. Although it rarely infects people, experts fear a mutation could make it easily transmissible, triggering a pandemic. From the start of 2003, 167 people, mostly in Asia, have died of the virus, according to the World Health Organization. In clinical trials, a two-shot series of the Sanofi vaccine provided protection in 45% of adults who received the highest dose, according to an FDA analysis this week. No serious side effects were detected among the 450 healthy adults who participated in a clinical test. However, some panel members were concerned that the trial was too small to reveal rare side effects. Some experts also worried about possible allergic reactions to the vaccine because it requires a massive dose — 12 times that of the seasonal inoculation.

Note: Who pays for and who profits from the purchase of these 20 million vaccine doses? It's pretty clear that the taxpayer covers the costs and the big drug companies make huge profits. Fear is quite useful for driving up profits. For lots more on profiteering from the avian flu, click here.

The gulf between rich and poor in the United States is yawning wider than ever, and the number of extremely impoverished is at a three-decade high. Based on the latest available U.S. census data from 2005, [a] McClatchy Newspapers analysis found that almost 16 million Americans live in "deep or severe poverty" defined as a family of four with two children earning less than 9,903 dollars — one half the federal poverty line figure. For individuals the "deep poverty" threshold was an income under 5,080 dollars a year. The number of severely poor Americans grew by 26% from 2000 to 2005. The surge in poverty comes alongside an unusual economic expansion. "Worker productivity has increased dramatically since the brief recession of 2001, but wages and job growth have lagged behind. At the same time, the share of national income going to corporate profits has dwarfed the amount going to wages and salaries. That helps explain why the median household income for working-age families, adjusted for inflation, has fallen for five straight years. These and other factors have helped push 43% of the nation's 37 million poor people into deep poverty — the highest rate since at least 1975," the report said. Since 2000, the number of severely poor — far below basic poverty terms — in the United States has grown "more than any other segment of the population. That was the exact opposite of what we anticipated when we began," said Steven Woolf of Virginia Commonwealth University, a study co-author. U.S. social programs are minimal compared to those of western Europe and Canada.

Pediatricians, gynecologists and even health insurers all call Gardasil, the first vaccine to prevent cervical cancer, a big medical advance. But medical groups, politicians and parents began rebelling after disclosure of a behind-the-scenes lobbying campaign by Gardasil's maker, Merck & Co., to get state legislatures to require 11- and 12-year-old girls to get the three-dose vaccine as a requirement for school attendance. Some parents' groups and doctors particularly objected because the vaccine protects against a sexually transmitted disease. Vaccines mandated for school attendance usually are for diseases easily spread through casual contact, such as measles and mumps. Bowing to pressure, Merck said Tuesday that it is immediately suspending its controversial campaign, which it had funded through a third party. Legislatures in roughly 20 states have introduced measures that would mandate girls have the vaccine to attend school. Texas Gov. Rick Perry on Feb. 2 issued an executive order requiring Texas girls entering the sixth grade as of 2008 get the vaccinations. Dr. Anne Francis, who chairs an American Academy of Pediatrics committee [stated] "I believe that their timing was a little bit premature," she said, "so soon after (Gardasil's) release, before we have a picture of whether there are going to be any untoward side effects." The country has been "burned" by some drugs whose serious side effects emerged only after they were in wide use, including Merck's withdrawn painkiller Vioxx. The vaccine also is controversial because of its price - $360 for the three doses required.

Note: $360 for every girl in school would amount to quite a hefty transfer of funds from taxpayers into the pockets of Merck. Could profit and campaign contributions be behind the move to make this mandatory?

Gov. Rick Perry on Thursday angrily defended his relationship with Merck & Co. and his executive order requiring that schoolgirls receive the drugmaker's vaccine against the sexually transmitted cervical-cancer virus. The Associated Press reported Wednesday that Perry's chief of staff had met with key aides about the vaccine on Oct. 16, the same day Merck's political action committee donated $5,000 to the governor's campaign. In issuing the order, the governor made Texas the first state to require the vaccine Gardasil for all schoolgirls. But many lawmakers have complained about his bypassing the Legislature altogether. The executive order has inflamed conservatives, who said it contradicts Texas' abstinence-only sexual education policies and intrudes into families' lives. Critics have previously questioned Perry's ties to Merck. Mike Toomey, Perry's former chief of staff, now lobbies for the drug company. And the governor accepted a total of $6,000 from Merck during his re-election campaign. Merck has waged a behind-the-scenes lobbying campaign to get state legislatures to require girls to get the three-dose vaccine to enroll in school. But on Tuesday the pharmaceutical company announced it was suspending the effort because of pressure from parents and medical groups. The Kentucky House on Thurday passed a bill that would require the vaccination for middle school girls unless their parents sign a form opposing it. Virginia lawmakers have also passed legislation requiring the vaccine, but the governor has not decided if he will sign it.

Note: The drug company lobby is the most powerful in the U.S., as reported by the former editor-in-chief of one of the most respected medical journals in the U.S. Click here for more.

The three top auditors overseeing work in Iraq told a House committee their review of $57 billion in Iraq contracts found that ... about $10 billion has been squandered by the U.S. government on Iraq reconstruction aid because of contractor overcharges and unsupported expenses. Of the $10 billion in overpriced contracts or undocumented costs, more than $2.7 billion were charged by Halliburton Co., the oil-field services company once headed by Vice President Dick Cheney. Federal investigators warned Thursday that significantly more taxpayer money is at risk. More than one in six dollars charged by U.S. contractors were questionable or unsupported, nearly triple the amount of waste the Government Accountability Office estimated last fall. "There is no accountability," said David M. Walker, who heads the auditing arm of Congress. "Organizations charged with overseeing contracts are not held accountable. Contractors are not held accountable. The individuals responsible are not held accountable." The investigators urged the Pentagon to reconsider its growing reliance on outside contractors. Layers of subcontractors, poor documentation and lack of strong contract management are rampant. Walker complained that GAO investigators have difficulty getting basic detail about reconstruction contracts such as expenses and subcontractors involved because many Pentagon divisions fail to consistently track or fully report them. Noting that auditors still have $300 billion of Iraq spending to review, Waxman said the total amount of waste, fraud and abuse "could be astronomical."

Note: To understand how so much money can go missing, read what a top U.S. general has to say here. And for major media articles claiming hundreds of billions of dollars are missing, click here.

Two of three former Enron Corp. traders accused of driving up energy prices during California's power crisis were each sentenced Wednesday to two years of court-supervised release in federal court. Timothy Belden ... was sentenced after pleading guilty in October 2002 to one count of conspiracy to commit wire fraud. Belden's plea was the first prosecution of anyone related to the West's energy crisis in 2000 and 2001. He had faced up to five years in prison, and must forfeit $2.1 million. The second defendant, Jeffrey Richter, was a lower-level trading manager ... who also pleaded guilty to two counts related to manipulating energy prices. He had faced up to five years and agreed to pay a $410,000 fine. Internal company memos describe how Belden's trading unit took power out of California at a time of rolling blackouts and shortages and sold it out of state to elude price caps. Enron bought California power at cheap, capped prices, routed it outside the state, then sold it back into California at vastly inflated prices. The crisis played a role in Pacific Gas & Electric Co.'s bankruptcy and will leave California consumers paying abnormally high electricity prices for years. Transcripts of Enron energy traders showed them openly discussing manipulating California's power market during profanity-laced telephone conversations in which they merrily gloated about ripping off “those poor grandmothers” during the energy crunch. On the calls, other traders openly and gleefully discussed creating congestion on transmission lines and taking generating units off-line to pump up electricity prices.

Note: So while California taxpayers cough up hundreds of millions of dollars as a result of Enron's scheming and thousands of employees across the U.S. lost their entire pensions, the result of the first prosecution of anyone related to the Enron scam is probation? For lots more on this, click here.

In the two decades since private equity firms first stormed the business world, they've been called a lot of things, from raiders to barbarians. But only [the Carlyle Group] has been tagged in the popular imagination with warmongering, treason, and acting as cold-eyed architects of government conspiracies. Carlyle, founded 20 years ago in the shadow of Washington's power centers, long went about its business far from the public eye. Its ranks were larded with the politically connected, including former Presidents, Cabinet members, even former British Prime Minister John Major. It used its partners' collective relationships to build a lucrative business buying, transforming, and selling companies -- particularly defense companies that did business with governments. Carlyle's radical makeover has turned the firm into the biggest fund-raising juggernaut the private equity world has ever seen. By the end of this year it expects to have an unprecedented $85 billion in investor commitments under management, up sixfold from 2001 and more than any other firm. [Founder David] Rubenstein sees the total swelling to as much as $300 billion by 2012. Make no mistake -- Carlyle is already massive. It owns nearly 200 companies that generate a combined $68 billion in revenue and employ 200,000 people. Last year it bought a new company approximately once every three days and sold one almost once a week -- all while dabbling in increasingly esoteric investments. Since its founding in 1987 it has generated annualized after-fee returns of 26%, compared with the industry average in the mid-teens.

Note: With former presidents including George H.W. Bush and many other top world politicians helping to sway huge military contracts, could this be considered a form of insider trading? Those 26% yearly returns are placing our tax monies in the hands of individuals and companies that are already among the wealthiest in the world. For lots more on manipulation of your tax money, click here. And for a Washington Post article showing Osama Bin Laden's brother met with George H.W. Bush at a Carlyle meeting one day before 9/11, click here.

A panel sponsored by the Council on Foreign Relations wants the United States to focus not on the defense of our own borders, but rather create what effectively would be a common border that includes Mexico and Canada. CHRISTINE ROMANS, CNN CORRESPONDENT: On Capitol Hill, testimony [is] calling for Americans to start thinking like citizens of North America and treat the U.S., Mexico and Canada like one big country. That's the view in a report called "Building a North American Community." It envisions a common border around the U.S., Mexico and Canada in just five years, a border pass for residents of the three countries, and a freer flow of goods and people. [Task force member Robert] PASTOR: What we hope to accomplish by 2010 is a common external tariff which will mean that goods can move easily across the border. We want a common security perimeter around all of North America. ROMANS: Security experts say folding Mexico and Canada into the U.S. is a grave breach of that sovereignty. [The report calls for] temporary migrant worker programs expanded with full mobility of labor between the three countries in the next five years. The idea here is to make North America more like the European Union. [CNN Anchor Lou] DOBBS: Americans must think that our political and academic elites have gone utterly mad at a time when three-and-a-half years, approaching four years after September 11, we still don't have border security. And this group of elites is talking about not defending our borders, finally, but rather creating new ones. It's astonishing.

Note: This agenda is being promoted in key political forums with practically no media reporting. For one of the few media articles reporting on this important topic, click here.

The 110th Congress opened with the passage of sweeping new rules intended to curb the influence of lobbyists by prohibiting them from treating lawmakers to meals, trips, stadium box seats or the discounted use of private jets. But it didn't take long for lawmakers to find ways to keep having fun while lobbyists pick up the tab. In just the last two months, lawmakers invited lobbyists to help pay for a catalog of outings: lavish birthday parties in a lawmaker's honor ($1,000 a lobbyist), martinis and margaritas at Washington restaurants (at least $1,000), a California wine-tasting tour (all donors welcome), hunting and fishing trips (typically $5,000), weekend golf tournaments ($2,500 and up), a Presidents Day weekend at Disney World ($5,000), parties in South Beach in Miami ($5,000), concerts by the Who or Bob Seger ($2,500 for two seats), and Broadway shows such as "Mary Poppins" and "The Drowsy Chaperone" (also $2,500 for two). The lobbyists and their employers typically end up paying for the events, but within the new rules. Instead of picking up the tab directly, lobbyists pay a political fundraising committee created by an individual politician and, in turn, the committee pays the lawmaker's way. Lobbyists say that the rules might even increase the volume of contributions flowing from K Street, where many lobbying firms have their offices, to Congress. Members of Congress are becoming more and more creative in finding ways to engage lobbyists to help pay for their campaigns.

Scientists and economists have been offered $10,000 each by a lobby group funded by one of the world's largest oil companies to undermine the UN climate change report. Letters sent by the American Enterprise Institute, an ExxonMobil-funded think tank with close links to the Bush Administration, offered the payments for articles that emphasise the shortcomings of the report. Travel expenses and additional payments were also offered. The institute has received more than $1.6 million from ExxonMobil - which yesterday announced a $50 billion annual profit, the biggest ever by a US company - and more than 20 of its staff have worked as consultants to the Bush Administration. A former head of ExxonMobil, Lee Raymond, is the vice-chairman of the institute's board of trustees.

Note: Why wasn't this important story covered by any major media in the U.S.? For an answer, click here.

The world's largest publicly owned oil company announced yesterday the largest corporate profit ever, but news of its near $40-billion (U.S.) windfall in 2006 sparked an angry backlash, coming on the eve of a major report blaming the use of fossil fuels for wreaking devastation on the planet. Exxon shares have risen by about 20 per cent in the past year. Exxon wasn't alone in unprecedented oil earnings. Royal Dutch Shell PLC, an Anglo-Dutch company, and U.S.-run Marathon Oil and Valero Energy, also posted best-ever annual results yesterday. And ConocoPhillips Co., also American, last week posted its highest profits. Profits at the five companies together totalled $91.1-billion -- in a year when drivers paid record prices for gasoline. Both Democratic and Republican members of Congress have also urged Exxon to end its funding of organizations that deny the existence of -- or minimize the seriousness of -- human-made global warming. Scientists yesterday accused the conservative American Enterprise Institute, which receives funding from Exxon, of offering scientists up to $10,000 for articles that undercut a report to be released today from the Intergovernmental Panel on Climate Change. Last month, the Union of Concerned Scientists ... said that Exxon has spent $16-million over the past 10 years financing organizations that deny the seriousness of climate change. Alden Meyer, a strategist with the group, compared Exxon's efforts to discredit the science of global warming to the tobacco companies' efforts to sow doubts about the link between smoking and lung cancer in order to protect their profits.

Note: Compare this Canadian article with the New York Times reporting of this record profit, or that of any other major U.S. newspaper. The U.S. press barely mentions that oil company gouging which took dollars from your pocket is what led to record profits. To understand why the U.S. press behaves in this way, click here.

The U.S. Food and Drug Administration said on Tuesday it would make organizational changes to improve internal communication about potential risks that emerge after a new drug reaches the market. The move is part of the agency's response to an Institute of Medicine (IOM) report that sharply criticized the FDA's drug safety oversight and called for more staffing, funding and power to police the drug industry. The September 2006 report also found a "dysfunctional" FDA structure that hindered the agency's ability to protect public health. The IOM experts said they found FDA officials had trouble managing scientific disagreements among staff and downplayed some concerns by safety reviewers who monitor drugs after they win approval. On Tuesday, the agency said it was "making specific organizational and management changes to increase communications among FDA review staff and safety staff." The announcement came as lawmakers prepare to debate critical funding legislation for the agency that could become a vehicle for drug safety reforms. The FDA had requested the IOM report after it came under harsh criticism for its handling of Merck & Co. Inc.'s withdrawn arthritis drug Vioxx and other medicines. Merck pulled Vioxx from the market in 2004, five years after its approval, because of a link to heart attacks and strokes.

The Middle Ages had the Knights Templar. The 18th century had the Masons and the Illuminati. Our modern age has golf-playing businessmen. [Jon] Ronson, a 35-year-old British writer, humorist and documentarian, kept reading and hearing about the "tiny elite [that] rules the world from inside a secret room" -- so he decided to go in search of it. He met with extremists of many stripes: Ku Klux Klansmen with a PR bent, Muslim rabble-rousers ... and others convinced that a New World Order meant the end of the world. He sought out the industrialists of groups such as the Bilderberg Group and Bohemian Grove. He wrote about his experiences in "Them." Ronson's extremists seem rather normal. Some are very much aware of how their views marginalize them. The people of "Them" are people who are all too human -- even if they would deny others their humanity. As the saying goes, just because you're paranoid doesn't mean someone's not out to get you. Ronson doesn't deny that many of the extremists in "Them" are, well, extreme. Many have put together half-baked theories that blame the troubles of the world on wealthy businessmen, usually a code word for Jews. Ronson, who's Jewish himself, sometimes found it awkward to listen to their views. Conspiracy theorists tend to be fearful, less educated, less tied in to the power structure. Meanwhile, the leaders of corporations and countries do meet as part of conferences sponsored by organizations such as the Trilateral Commission and the Bilderberg Group. While researching a Bilderberg Group meeting, [Ronson] was chased through parts of Portugal by shadowy security men. He found out just how thin the membrane between "us" and "them" may be.

Note: Them is by far the most balanced, entertaining book you are likely to find on conspiracy theorists. It pokes a lot of fun both at the conspiracy theorists and at the powerful secret groups which he finds to be deluded almost as much as the conspiracy theorists themselves.

Secret emails reveal that the UK's biggest drug company distorted trial results of an anti-depressant, covering up a link with suicide in teenagers. GlaxoSmithKline (GSK) attempted to show that Seroxat worked for depressed children despite failed clinical trials. And that GSK-employed ghostwriters influenced 'independent' academics. GSK faces action in the US where bereaved families have joined together to sue the company. As a result, GSK has been forced to open its confidential internal archive. Karen Barth Menzies is a partner in one of the firms representing many of the families. She has examined thousands of the documents which are stored, box upon box, in an apartment in Malibu, California. She said: "Even when they have negative studies that show that this drug Seroxat is going to harm some kids they still spin that study as remarkably effective and safe for children." An email from a public relations executive working for GSK ... said: "Originally we had planned to do extensive media relations surrounding this study until we actually viewed the results. Essentially the study did not really show it was effective in treating adolescent depression, which is not something we want to publicise." Seroxat was banned for under 18s in 2003 after the MHRA revealed that GSK's own studies showed the drug actually trebles the risk of suicidal thoughts and behaviour in depressed children.

Note: For more reliable information on how the drug companies put profits ahead of your health, click here.

There are no magic bullets in the fight against cancer: that's the first thing every responsible scientist mentions when discussing a possible new treatment, no matter how promising. If there were a magic bullet, though, it might be something like dichloroacetate, or DCA, a drug that kills cancer cells by exploiting a fundamental weakness found in a wide range of solid tumors. So far, though, it kills them just in test tubes and in rats infected with human cancer cells; it has never been tested against cancer in living human beings. DCA ... is an existing drug whose side effects are well-studied and relatively tolerable. Also, it's a small molecule that might be able to cross the blood-brain barrier to reach otherwise intractable brain tumors. Within days after a technical paper on DCA appeared in the journal Cancer Cell last week, the lead author, Dr. Evangelos Michelakis of the University of Alberta, was deluged with calls and e-mails from prospective patients—to whom he can say only, “Hang in there.” DCA is a remarkably simple molecule. It acts in the body to promote the activity of the mitochondria. Researchers have assumed that the mitochondria in cancer cells were irreparably damaged. But Michelakis wondered if that was really true. With his colleagues he used DCA to turn back on the mitochondria in cancer cells—which promptly died. One of the great things about DCA is that it's a simple compound, in the public domain, and could be produced for pennies a dose. But that's also a problem, because big drug companies are unlikely to spend a billion dollars or so on large-scale clinical trials for a compound they can't patent.

Note: Read a 2010 follow-up by Dr. Michelakis with promising results and watch a 10-minute video. Explore the DCA website. Why didn't other mass media report this major story? Why aren't many millions of dollars being poured into research? Notice even Newsweek acknowledges the drug companies are not interested in finding a cure for cancer if they can't make a profit from it. Some suspect the drug companies have even suppressed cancer cures found in the past. See one amazing example of this. For more, see these major media articles on potential cancer cures.

Dr. Walter Bernard Coffey of San Francisco was again asking the State of New York's Department of Social Welfare permission to open a cancer research laboratory and clinic at Huntington, L. I. His cohorts surrounded him. Opposed were Dr. John Augustus Hartwell, president of the New York Academy of Medicine, spokesman for organized Medicine, and his cohorts. The simple question was: Should the State authorize the cancer clinic? But in the train of that simple question came a most extraordinary range of considerations—the nature and cause of cancer; the nature and authenticity of the Coffey-Humber cancer treatment; medical ethics, human nature, public policy, money, fame, and even national politics. Dr. Coffey ... is chief surgeon of Southern Pacific Co. He has 600 doctors working under him. They care for 70,000 railroad men and their families. Dr. John Augustus Hartwell, 61, president of the New York Academy of Medicine ... and most of his associates want Drs. Coffey & Humber and their cancer extract kept away from New York. They fear that the hope of a Coffey-Humber cancer cure will persuade the cancerous to abandon the orthodox treatment of surgery, X-rays and radium. Very quickly after a sufferer gets a Coffey-Humber injection, his pain quiets, and in 71% of the cases disappears. In most of the cases who do not die (Drs. Coffey & Humber will treat only the moribund, cases rejected as hopeless by at least two reputable doctors), the cancer becomes necrotic, ceases to smell, and sloughs off leaving a clean hole. That undeniably happens. Why that happens is debatable.

Note: To read how permission for the innovative cancer clinic was eventually refused, click here. If you want to understand how politics and big money prevented the legitimate study of promising cancer cures back in the 1930s, this article is a highly revealing "must read."

Drs. Coffey & Humber ... last year cautiously announced that they were alleviating hopeless cases of cancer by means of adrenal cortex extract derived from sheep. The Hearst press recognized the kernel of news in this announcement and puffed it so that thousands of cancer victims abandoned the orthodox treatment of surgery, X-rays and radium, rushed for the sure-cure. The two doctors were amazed, but nonetheless swam with the tide of publicity and patients. They opened auxiliary clinics at Los Angeles and Long Beach. They went before a Senate committee to argue for Government aid for cancer research. They gained a patent for their extract. Mrs. Grace Hammond Conners ... gave Drs. Coffey & Humber her $1,000,000 estate, "The Monastery," at Huntington, L. I. Although Dr. Hartwell & friends who last week opposed opening "The Monastery" as a clinic "do not for a minute question the sincerity of Drs. Coffey and Humber in believing they have something of value," the critics "do question the way they have handled their work." The New York men are certain that their San Francisco colleagues have had no training to qualify for research in "the most complex field that exists" in medicine. They do not believe that adrenal cortex extract will cure cancer or that it has value in cancer treatment. They fear that the Californians will experiment on New York humans, hence want them (or at least their methods; excluded, to remain in California where patients are "abundantly available." This was obviously a campaign to ostracize Drs. Coffey & Humber from Manhattan's vicinity. It was conducted ... "by persons who had their own methods, hospitals and funds."

Note: The doctors eventually not only were denied permission to open a cancer clinic for their promising work, they were stripped of the $1 million dollar estate donated to them (worth about $15 million in current U.S. dollars). For the full, fascinating story, click here.

The two sides in the debate over genetically modified crops issued warring reports assessing the first decade of the technology this week, as the industry's sunny view clashed with the darker vision of critics. The world's farmland planted with biotechnology crops reached 252 million acres in 2006, the industry-backed International Service for the Acquisition of Agri-Biotech Applications calculated in a report ... that promotes the products as solutions for hunger and future fuel demand. The report concluded that biotechnology boosts crop yields and benefits the environment. That view was challenged by Friends of the Earth International and the Center for Food Safety in a report released Wednesday. The two groups argued that engineered plants don't produce larger harvests than conventional varieties, are often more vulnerable to drought and have increased the use of pesticides. The United States and Argentina host about 70 percent of the world's biotech crop acreage, both sides said. But adoption of the technology is growing at a faster rate in developing countries than in industrialized nations, according to the International Service. About 10 million farmers in 22 countries sow genetically modified crops, it said. The dominant biotech crop is soybeans, with 57 percent of world acreage, followed by maize, cotton and canola. Opponents said the crops are mainly a boon to agribusiness and big agricultural chemical companies trying to increase sales of seeds, weed-killers and bug sprays. Biotech crop seeds are often engineered to be resistant to the herbicides or pesticides sold by the same company.

Note: For reliable information showing that you may be eating genetically modified food every day which scientific experiments have repeatedly demonstrated can cause sickness and even death, click here.

In results that "astounded" scientists, an inexpensive molecule known as DCA was shown to shrink lung, breast and brain tumours in both animal and human tissue experiments. The study was published yesterday in the journal Cancer Cell. "I think DCA can be selective for cancer because it attacks a fundamental process of cancer that is unique to cancer cells," said Dr. Evangelos Michelakis, a professor at the Edmonton university's medical school and one of the study's key authors. The molecule appears to repair damaged mitochondria in cancer cells. "When a cell is getting too old or doesn't function properly, the mitochondria are going to induce the cell death," lead study author Sebastien Bonnet said yesterday. Bonnet says DCA – or dichloroacetate – appears to reverse the mitochondrial changes in a wide range of cancers. "One of the really exciting things about this compound is that it might be able to treat many different forms of cancer because all forms of cancer suppress mitochondrial function," Michelakis said. Bonnet says DCA may also provide an effective cancer treatment because its small size allows easy absorption into the body, ensuring it can reach areas that other drugs cannot, such as brain tumours. Because it's been used to combat other ailments ... DCA has been shown to have few toxic effects on the body. Its previous use means it can be immediately tested on humans. Unlike other cancer drugs, DCA did not appear to have any negative effect on normal cells. It could provide an extremely inexpensive cancer therapy because it's not patented. But ... the lack of a patent could lead to an unwillingness on the part of pharmaceutical companies to fund expensive clinical trials.

Note: Even these scientists realize that though this discovery could be a huge benefit to mankind, because the drug companies will lose profits, they almost certainly will not fund studies. Expensive AIDS drugs with promising results, on the other hand, are rushed through the studies to market. For more reliable, verifiable information on how hugely beneficial health advances are shut down to keep profits high, click here and here.

Data supplied by tobacco companies strongly suggest that in recent years manufacturers deliberately boosted nicotine levels in cigarettes to more effectively hook smokers, Harvard researchers conclude in a study being released today. The companies increasingly used tobacco richer in nicotine and made design changes to give smokers more puffs per cigarette, according to the analysis from the Harvard School of Public Health. The report expands on a landmark Massachusetts Department of Public Health study issued last August showing that the amount of nicotine that could be inhaled from cigarettes increased an average of 10 percent from 1998 through 2004. A 1996 state law required cigarette makers to test the nicotine that could be inhaled from their products, and the state ordered the use of machines that simulate a typical smoker's puffing. The Harvard researchers, who corroborated the basic findings of the state study, wanted to determine why cigarettes were delivering more nicotine. "Industry says it's changed," said Greg Connolly, an author of the Harvard study. "They've changed -- maybe for the worse." The Harvard study relies on information supplied by the industry. "It was systematic, it was pervasive, it involved all the manufacturers, and it was by design," said Dr. Howard Koh, an associate dean at the Harvard School of Public Health and an author of the study. Another author said that the likelihood that the nicotine increase happened by chance was less than 1 in 1,000.

Important Note: Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.